Cutiss AG

Our solution –
Personalized, bio-engineered, dermo-epidermal skin grafts

After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.

Cutiss AG

Our solution –
Personalized, bio-engineered, dermo-epidermal skin grafts

After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.

Cutiss AG

Technology

To bio-engineer denovoSkin™, a small biopsy of healthy skin is harvested from the patient. The biopsy is processed to isolate epidermal and dermal cells. The cells are expanded in vitro, and thereafter used in combination with a hydrogel to create a dermo-epidermal skin graft. denovoSkin™ is now ready to be transplanted on the patient’s wounds. The safety trials for denovoSkin™ have been completed. The efficacy trials are supported by Wyss Zurich.

Cutiss AG

Potential

denovoSkin™ has a large potential. It could be of great benefit for patients with burns, traumas, that undergo reconstructive or plastic procedures, as well as for patients with chronic ulcers or congenital malformations that lead to skin-related problems.

denovoSkin™ is a patented, personalized, autologous bio-engineered human skin graft classified as Advanced Therapy Medicinal Product (ATMP). It is engineered in large quantities starting-off from a stamp-sized skin biopsy of the patient, thus solving the donor site shortage issue. Moreover, because of its dermo-epidermal structure, denovoSkin™ leads to minimal scarring after transplantation.

Its outstanding performance could considerably reduce or even avoids further corrective interventions, allowing for considerable savings. denovoSkin™ is also granted with Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA.

Cutiss AG

get involved

Every year, large burns or a large skin transplantation tremendously affect the lives of millions of patients, pediatric patients, and their relatives. Indeed, standard of care is scarce and, still today, results too often into scars. CUTISS aims to offer the best possible skin replacement, denovoSkin: a safe, effective, accessible and permanent skin tissue treatment.

Our vision is big but our journey is challenging! It takes lots of people’s trust, support and commitment to succeed!

With your donation, you could support CUTISS’ research and clinical programs. Of course, you could also support a specific project or the work of a young scientist in the team.

Take part to the journey, come on board at CUTISS AG and help us change the lives of burn survivors!

Please contact us to involve yourself or use directly the following IBAN to contribute: Zürcher Kantonalbank, 8010 Zürich IBAN CH02 0700 0110 0065 8561 4

We thank you very much!

Scroll to Top

Newsletter

Would you like to contact us as a journalist?

This website uses cookies to ensure you get the best experience on our website.